Analysis of the Pharmacokinetic Boosting Effects of Ritonavir on Oral Bioavailability of Drugs in Mice

Vectorial Transport of Fexofenadine across Caco-2 Cells: Involvement of Apical Uptake and Basolateral Efflux Transporters

(2011) Xin Ming et al.   MOLECULAR PHARMACEUTICS

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

(2010) Ruben C. Hartkoorn et al.   Pharmacogenetics and Genomics

Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers

(2010) Yumiko Akamine et al.   XENOBIOTICA

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1

(2010) P. Annaert et al.   XENOBIOTICA

Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

(2009) T. Tachibana et al.   XENOBIOTICA

Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P-Glycoprotein Activities

(2008) ED Kharasch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers

(2008) Jennifer J Kiser et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine

(2008) S. Matsushima et al.   MOLECULAR PHARMACOLOGY

Species Differences in In Vitro and In Vivo Small Intestinal Metabolism of CYP3A Substrates

(2007) Hiroshi Komura et al.   JOURNAL OF PHARMACEUTICAL SCIENCES